PD31-02 METFORMIN USE AND PROSTATE CANCER RISK

Field: Medicine (Health Sciences)

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History I1 Apr 2014PD31-02 METFORMIN USE AND PROSTATE CANCER RISK Mark A. Preston, Anders H. Riis, Vera Ehrenstein, Rodney H. Breau, Julie Batista, Aria F. Olumi, Lorelei A. Mucci, Hans-Olov Adami, and Henrik T. Sorensen Mark A. PrestonMark A. Preston More articles by this author , Anders H. RiisAnders H. Riis More articles by this author , Vera EhrensteinVera Ehrenstein More articles by this author , Rodney H. BreauRodney H. Breau More articles by this author , Julie BatistaJulie Batista More articles by this author , Aria F. OlumiAria F. Olumi More articles by this author , Lorelei A. MucciLorelei A. Mucci More articles by this author , Hans-Olov AdamiHans-Olov Adami More articles by this author , and Henrik T. SorensenHenrik T. Sorensen More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.2261AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Metformin is a medication commonly used to treat Type II diabetes and that may decrease prostate cancer risk by reducing hyperinsulinemia-associated carcinogenesis. Our objective was to evaluate the association between metformin use and incidence of prostate cancer. METHODS We used the Danish Cancer Registry and the Aarhus University Prescription Database to conduct a nested case–control study among men who resided in northern Denmark from January 1989 to December 2011. We identified 12,226 cases of prostate cancer and used risk-set sampling to select 10 population controls per case (n= 122,260) from among men alive on the index date and born in the same year as the case. Metformin exposure was assessed using prescriptions redeemed before the index date. A sensitivity analysis was conducted using subjects who had prostate-specific antigen (PSA) testing in a 5-year period prior to one year before index date. Odds ratios (OR) for the association between metformin use and risk of prostate cancer, and 95% confidence intervals (CI) were estimated using conditional logistic regression to examine the association between metformin use and prostate cancer occurrence, controlling for severity of diabetes, comorbidities and use of other medications. RESULTS The median age of cases was 71.7 years (range: 34.9-99.2 years) and of controls was 71.7 years (range: 34.2-99.9 years). Metformin users were found to be at decreased risk of prostate cancer compared with men who never used metformin (Adjusted OR 0.84, 95% CI 0.74-0.96). Diabetics on no medication (Adjusted OR 0.98, 95% CI 0.89-1.09) and users of other oral hypoglycemics (Adjusted OR 0.98, 95% CI 0.86-1.10) did not have a reduced risk of prostate cancer while users of insulin did (Adjusted OR 0.77, 95% CI 0.64-0.93). In the PSA-tested group, metformin use was associated with decreased risk of prostate cancer compared with non-use (OR 0.66, 95% CI 0.51-0.86). Diabetics on no medication (Adjusted OR 1.03, 95% CI 0.86-1.24), users of other oral hypoglycemics (Adjusted OR 0.92, 95% CI 0.70-1.20) and insulin users (Adjusted OR 0.83, 95% CI 0.56-1.24) did not have a significantly reduced risk of prostate cancer. CONCLUSIONS Metformin use was associated with a decreased incidence of prostate cancer in this population-based study while diabetics using other oral hypoglycemics had no associated decrease in prostate cancer incidence. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e831-e832 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Mark A. Preston More articles by this author Anders H. Riis More articles by this author Vera Ehrenstein More articles by this author Rodney H. Breau More articles by this author Julie Batista More articles by this author Aria F. Olumi More articles by this author Lorelei A. Mucci More articles by this author Hans-Olov Adami More articles by this author Henrik T. Sorensen More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...